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Serum free thiols predict cardiovascular
events and all-cause mortality in the
general population: a prospective cohort
study
Amaal E. Abdulle1†, Arno R. Bourgonje2†, Lyanne M. Kieneker3, Anne M. Koning4, S. la Bastide-van Gemert5,
Marian L. C. Bulthuis4, Gerard Dijkstra2, Klaas Nico Faber2, Robin P. F. Dullaart6, Stephan J. L. Bakker3,
Reinold O. B. Gans1, Ron T. Gansevoort3, Douwe J. Mulder1, Andreas Pasch7† and Harry van Goor4*†
Abstract
Background: Serum free thiols (R-SH, sulfhydryl groups) reliably reflect systemic oxidative stress. Since serum free
thiols are rapidly oxidized by reactive species, systemic oxidative stress is generally associated with reduced
serum free thiol levels. Free thiols associate with favorable disease outcomes in many patient cohorts, and the
current hypothesis is that oxidative stress might also play an important role in cardiovascular disease. In this study,
we aimed to establish the role of serum free thiols in the general population by investigating their relationship with
the risk of cardiovascular (CV) events and all-cause mortality.
Methods: Participants (n = 5955) of the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) cohort
study from the general population were included. At baseline, serum levels of free thiols were quantified and
adjusted to total protein levels. Protein-adjusted serum free thiol levels were studied for their associations with
clinical and biochemical parameters, as well as with the risk of CV events and all-cause mortality.
Results: The mean protein-adjusted serum free thiol level was 5.05 ± 1.02 μmol/g of protein. Protein-adjusted
serum free thiols significantly predicted the risk of CV events, even after adjustment for potential confounding
factors (hazard ratio [HR] per doubling 0.68 [95% confidence interval [CI] 0.47–1.00], P = 0.048). Similarly, protein-
adjusted serum free thiols were significantly predictive of the risk of all-cause mortality (HR per doubling 0.66 [95%
CI 0.44–1.00], P = 0.050). Stratified analyses revealed lower HRs for subjects with a lower body mass index (BMI),
without hypertension, and without diabetes. Conversely, HRs were lower in subjects with albuminuria.
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Conclusions: In this large population-based cohort study, serum free thiols significantly predicted the risk of CV
events and all-cause mortality. Our results highlight the potential significance and clinical applicability of serum free
thiols since they are amendable to therapeutic intervention.
Keywords: Oxidative stress, Free thiols, Cardiovascular disease, Mortality, Population study
Background
Cardiovascular disease (CVD) is among the leading causes
of morbidity and mortality globally, and during the past
decade, the number of CVD-associated deaths has
increased by 12.5% [1, 2]. Although a large proportion of
the overall cardiovascular risk can be explained by known
risk factors (e.g., smoking, hypertension, obesity, diabetes,
and hypercholesterolemia), the pathogenesis of CVD still
remains incompletely understood [3]. Current approaches
to reduce the CVD burden have focused on encouraging
healthier lifestyles. Other approaches have focused on the
early identification of patients who are at increased risk of
CVD. These latter strategies have faced multiple problems,
including limited availability of non-invasive predictive
biomarkers to assess the risk of cardiovascular (CV) events
or mortality.
Oxidative stress is defined as the imbalance between the
production of reactive oxygen species (ROS) and antioxi-
dants. Although ROS, a collective term for oxygen-
containing reactive species, are important signaling mole-
cules regulating a variety of physiological processes, over-
production of ROS leads to cellular damage and tissue
destruction. Chronic oxidative stress can easily and reli-
ably be monitored as the depletion of serum free thiols,
since they are readily oxidized by reactive species [4–6]. In
support, overproduction of ROS, as reflected by reduced
levels of free thiols, is frequently observed in human dis-
ease (like in chronic kidney disease, chronic heart failure,
diabetes, cancer, systemic sclerosis, and Crohn’s disease)
that is typically associated with oxidative stress [7–10].
Free thiol groups (R-SH, sulfhydryl groups) are thought to
play a protective role against oxidative stress through ROS
scavenging and are an important component of the
in vivo antioxidant buffer capacity. Studies from our cen-
ter have demonstrated that higher levels of serum free
thiols (i.e., lower levels of oxidative stress) are associated
with favorable outcomes in patients with chronic heart
failure [7], as well as with a beneficial outcome and cardio-
vascular risk profile in renal transplant recipients [11].
Oxidative stress has been acknowledged to play an im-
portant role in CVD, and conditions promoting oxidative
stress have also been associated with risk of CVD [12].
Therefore, we hypothesized that serum free thiol groups,
as overall markers of systemic oxidative stress, might have
merit as a read-out of cardiovascular health in the general
population. Moreover, free thiols might be a valuable
indicator of the risk of all-cause mortality and risk of CV
events, which could be applicable for risk stratification
aimed to reduce CVD burden. Therefore, the aim of this
study was to determine the predictive value of serum
levels of free thiols regarding the risk of cardiovascular
events and all-cause mortality in the general population.
Methods
Study population
This study used data from the Prevention of REnal and
Vascular ENd-stage Disease (PREVEND) cohort study
[13]. This is a large, prospective population-based cohort
study with participants from the northern part of the
Netherlands. The PREVEND study was set up to investi-
gate cardiovascular and renal disease outcomes focused
on albuminuria as the main risk factor. From 1997 to
1998, 85,421 inhabitants aged 28–75 years from the
northern parts of the Netherlands received a question-
naire asking information about demographics, medica-
tion use, cardiovascular disease, and pregnancy,
including a request to supply an early morning urine
sample. Participants who had a previous diagnosis of
type 1 diabetes mellitus and insulin-treated type 2 dia-
betes mellitus and pregnant women were excluded from
the study. In total, 40,856 subjects responded to the
questionnaire and were analyzed for urinary albumin
concentrations. Study participants having urinary albu-
min concentrations ≥ 10 mg/L (n = 6000) were invited to
visit the outpatient research clinic of the University
Medical Center Groningen (UMCG), as well as a ran-
dom selection of participants with urinary albumin con-
centrations < 10 mg/L (n = 2592). Therefore, the
PREVEND study consisted of an initial total of 8592 par-
ticipants who completed the full study program [14].
However, serum samples from 6136 participants were
collected during the second visit (2001–2003, referred to
as the baseline visit in the present study). Participants
who had a CV event between visit 1 and visit 2 (n = 181)
were excluded from the analyses given the fact that re-
events were not registered for these subjects. However,
participants with a known cardiovascular disease prior
to visit 2, who did not experience a CV event between
visit 1 and visit 2, were included. Therefore, a total of
5955 participants were included in the current study.
This study was approved by the Institutional Review
Board (IRB) (full name in Dutch: “Medisch Ethische
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Toetsingscommissie” [METc]) of the UMCG. The study
was conducted in accordance with the principles of the
Declaration of Helsinki (2013), and all study participants
provided written informed consent.
Data collection
All study participants visited the outpatient research clinic
of the University Medical Center Groningen (UMCG),
Groningen, the Netherlands. During the first visit, partici-
pants were requested to complete a questionnaire contain-
ing information about demographics, health status, history
of cardiovascular disease (CVD), medication usage, and
lifestyle habits (e.g., smoking habits), and anthropometric
measurements were performed as well. At the second
visit, systolic and diastolic blood pressure was automatic-
ally measured every minute for a period of 8min in a
supine position (Dinamap XL Model 9300 series device,
Johnson & Johnson Medical, Tampa, FL). Blood pressure
was defined as the average of the last two measurements.
Furthermore, serum samples were collected, and patients
were asked to collect 24-h urine after they were provided
with both oral and written instructions. Serum samples
were stored at − 80 °C, while urine samples were stored at
− 20 °C until further analysis.
Laboratory measurements
High-sensitive C-reactive protein (hsCRP) and urinary
albumin excretion (UAE) were measured by nephelometry
(Dade Behring Diagnostics, Marburg, Germany). UAE was
measured twice in two different 24-h urine collections, and
the average was taken for analyses. Serum total cholesterol
and fasting glucose were measured by dry chemistry (East-
man Kodak, Rochester, NY, USA). Serum total protein was
measured using spectrophotometry (Roche Modular,
Roche, Mannheim, Germany). High-density lipoprotein
(HDL) cholesterol was measured using a homogeneous
method (direct HDL, AerosetTM System, Abbott Labora-
tories, Abbott Park, IL, USA). Low-density lipoprotein
(LDL) cholesterol was determined by the Friedewald for-
mula (if triglycerides ≤ 4.5mmol/L). Triglycerides were
measured with an enzymatic method. Serum creatinine was
measured enzymatically (Roche Modular, Roche Diagnos-
tics, Mannheim, Germany). Serum cystatin C was measured
using the Gentian Cystatin C Immunoassay (Gentian AS,
Moss, Norway) on a modular analyzer (Roche Diagnostics).
Cystatin C was directly calibrated using standards from the
manufacturer’s supplies (according to the International
Federation of Clinical Chemistry Working Group for
Standardization of Serum Cystatin C) [15].
Serum free thiol measurements
Measurement of serum free thiols (R-SH, sulfhydryl
groups) was performed as previously described, with
minor modifications [16, 17]. After thawing, samples were
4-fold diluted using 0.1M Tris buffer (pH 8.2). Back-
ground absorption was measured at 412 nm using the
Varioskan microplate reader (Thermo Scientific, Breda,
the Netherlands), together with a reference measurement
at 630 nm. Subsequently, 20 μL 1.9mM 5,5′-dithio-bis (2-
nitrobenzoic acid) (DTNB, Ellman’s reagent, CAS no. 69-
78-3, Sigma Aldrich Corporation, St. Louis, MO, USA)
was added to the samples in 0.1M phosphate buffer (pH
7.0). After an incubation time of 20min at room
temperature, absorbance was measured again. The final
serum free thiol concentrations were established by paral-
lel measurement of an L-cysteine (CAS no. 52-90-4, Fluka
Biochemika, Buchs, Switzerland) calibration curve (range
from 15.6 to 1000 μM) in 0.1M Tris/10mM EDTA (pH
8.2). Intra- and interassay coefficients of variation (CV) of
serum free thiol measurements were 1.9% and 5.0%, re-
spectively. Finally, serum free thiol concentrations were
adjusted to total serum protein (measured according to
standard procedures) by calculating the free thiol/total
protein ratio (μmol/g of protein). This adjustment was
performed since serum proteins harbor the largest
amount of free thiols and therefore greatly determine the
quantity of potentially detectable free thiol groups [18].
Study outcomes and definitions
Estimated glomerular filtration rates (eGFR) were calcu-
lated using the combined creatinine cystatin C-based
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation [19]. Type 2 diabetes mellitus
(T2DM) was defined as a fasting glucose level ≥ 7.0 mM
or the use of antidiabetic medications according to the
guidelines of the American Diabetic Association (ADA).
Hypercholesterolemia was defined as a serum total chol-
esterol level > 6.5 mmol/L, serum HDL cholesterol
level < 0.9 mmol/L, or the use of lipid-lowering drugs at
baseline. Fatal and non-fatal cardiovascular events (CV)
(i.e., combined outcomes of acute myocardial infarction
(AMI), acute or subacute ischemic heart disease (IHD),
coronary artery bypass grafting (CABG), percutaneous
transluminal coronary angioplasty (PTCA), intracerebral
hemorrhage, other intracranial hemorrhages, subarach-
noid hemorrhage, occlusion and stenosis of precerebral
or cerebral arteries, and other vascular interventions
such as carotid desobstruction, aorta peripheral bypass
surgery, or percutaneous transluminal femoral angio-
plasty) and all-cause mortality were considered primary
endpoints of the current study. These outcomes were
determined by using information from the Dutch
National Registry of all hospital discharge diagnoses (Pris-
mant). This information was classified in accordance with
the International Statistical Classification of Diseases
(ICD-10) and the International Classification of Health In-
terventions [20]. In addition, the classical 3-point major
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adverse cardiovascular events (3P-MACE) was considered
as the composite endpoint for CV events, consisting of
fatal CV events, non-fatal myocardial infarction, and non-
fatal stroke [21].
Statistical analysis
Data analysis was performed using the SPSS Statistics
25.0 software package (SPSS Inc., Chicago, IL, USA),
Stata 15.1 (Stata Corp LLC, College Station, TX, USA),
and R version 3.5.2. (Vienna, Austria). Data visualization
was performed using GraphPad Prism 5.0 (GraphPad
Software, San Diego, CA, USA) and RStudio (version
1.2.1335; RStudio, Boston, MA). Demographic and clin-
ical characteristics were presented as mean ± standard
deviation (SD), median (interquartile range [IQR]) in
case of skewed variables, or proportions n with corre-
sponding percentages (%). Normality was assessed and
visualized using histograms and normal probability plots
(Q-Q plots). Between-group comparisons for continuous
variables were performed using one-way analysis of vari-
ance (ANOVA) or Kruskal-Wallis tests, while for nom-
inal variables, chi-square tests were performed, as
appropriate. Protein-adjusted serum free thiol concen-
trations were 2log-transformed to facilitate result
Table 1 Demographic and clinical characteristics of the study population
Total, N = 5955 T1, N = 1985 T2, N = 1985 T3, N = 1985 P value
Serum free thiol (μmol/g) levels (adjusted for protein) 5.05 (± 1.02) μmol/g < 4.65 μmol/g 4.65–5.46 μmol/g > 5.46 μmol/g
Age (years) 51.6 (43.3–61.7) 57.6 (47.8–66.6) 51.1 (43.4–59.8) 47.7 (41.1–55.3) < 0.001
Female, n (%) 3038 (51.0%) 1084 (54.6%) 1013 (51.0%) 941 (47.4%) < 0.001
Blood pressure
SBP (mmHg) 126 (± 19) 129 (± 20) 125 (± 18) 123 (± 17) < 0.001
DBP (mmHg) 73 (± 9) 74 (± 9) 73 (± 9) 73 (± 9) < 0.001
Heart rate (bpm) 68 (± 10) 69 (± 11) 69 (± 10) 68 (± 10) 0.44
Obesity variables
BMI (kg/m2) 26.0 (23.6–28.9) 26.8 (24.3–29.9) 26.0 (23.6–28.7) 25.3 (23.0–28.0) < 0.001
Waist circumference (cm) 91.0 (82.0–100.0) 94.0 (85.0–102.0) 91.0 (82.0–100.0) 89.0 (81.0–98.0) < 0.001
Smoking, n (%) < 0.001
Never, n (%) 1757 (29.5%) 583 (29.4%) 578 (29.1%) 596 (30.0%)
Current, n (%) 1655 (27.8%) 494 (24.9%) 538 (27.1%) 623 (31.4%)
Former, n (%) 2472 (41.5%) 887 (44.7%) 848 (42.7%) 737 (37.1%)
History of cardiovascular disease, n (%) 217 (3.6%) 100 (5.0%) 69 (3.5%) 48 (2.4%) < 0.001
Diabetes, n (%) 144 (2.4%) 76 (3.8%) 34 (1.7%) 34 (1.7%) < 0.001
Medication, n (%)
Antihypertensive drugs, n (%) 1037 (17.4%) 481 (24.2%) 307 (15.5%) 249 (12.5%) < 0.001
Lipid-lowering drugs, n (%) 371 (6.2%) 155 (7.8%) 126 (6.3%) 90 (4.5%) < 0.001
Antidiabetic drugs, n (%) 78 (1.3%) 40 (2.0%) 19 (1.0%) 19 (1.0%) 0.006
Laboratory measurements
Total cholesterol (mmol/L) 5.5 (± 1.0) 5.5 (± 1.0) 5.5 (± 1.0) 5.4 (± 1.1) < 0.001
HDL (mmol/L) 1.2 (1.0–1.5) 1.2 (1.1–1.5) 1.2 (1.0–1.4) 1.2 (1.0–1.4) 0.68
LDL (mmol/L) 3.4 (2.7–4.2) 3.5 (2.8–4.2) 3.3 (2.7–4.1) 3.3 (2.6–4.1) 0.20
Triglycerides (mmol/L) 1.1 (0.8–1.6) 1.1 (0.8–1.6) 1.1 (0.8–1.6) 1.0 (0.8–1.6) 0.001
hsCRP (mg/L) 1.3 (0.6–2.9) 1.6 (0.8–3.9) 1.3 (0.6–2.8) 1.0 (0.5–2.3) < 0.001
Fasting glucose (mmol/L) 4.7 (4.4–5.2) 4.8 (4.5–5.3) 4.7 (4.4–5.2) 4.7 (4.4–5.2) < 0.001
eGFR (mL/min/1.73 m2) 94.5 (82.2–104.7) 86.5 (74.7–99.0) 95.0 (83.9–14.0) 99.8 (90.1–108.2) < 0.001
Albuminuria (mg/L) 8.5 (6.0–15.0) 9.3 (6.2–19.0) 8.4 (6.0–14.0) 8.1 (5.95–13.1) < 0.001
CV events, n (%) 402 (6.8%) 184 (9.3%) 127 (6.4%) 91 (4.6%) < 0.001
Mortality, n (%) 316 (5.3%) 171 (8.6%) 85 (4.3%) 60 (3.0%) < 0.001
Data are presented as mean ± SD, proportions n with corresponding percentages (%) or median (IQR)
P values in bold indicate statistical significance
SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein, hsCRP high-sensitive C-
reactive protein, eGFR estimated glomerular filtration rate, CV cardiovascular
Abdulle et al. BMC Medicine          (2020) 18:130 Page 4 of 12
interpretation (per doubling). Survival distributions were
assessed for tertiles of protein-adjusted serum free thiol
concentrations using Kaplan-Meier curves and com-
pared with log-rank tests. Survival time was defined
from baseline (time of serum sample collection) until
the date of the last examination that participants
attended: the incidence of the cardiovascular (CV) event,
death, or January 1, 2010 (end of follow-up). Cox
proportional hazards regression analyses were performed
to assess the association between protein-adjusted
serum free thiols and the risk of CV events or all-cause
mortality. The results were expressed as hazard ratios
(HRs) with corresponding 95% confidence intervals. Uni-
variable associations were followed by multivariable Cox
regression models to adjust for potential confounding
factors and stratified analyses to assess HRs across sev-
eral subgroups. To evaluate the discriminative capacity
of Cox regression models, receiver operating characteris-
tics (ROC) analyses were performed by calculating the
Harrell C index for the various models. The Harrell C
index represents the area under the ROC curve (AUC)
and is compatible with time-to-event data. Finally, Cox
regression analyses were repeated with restricted cubic
splines with three knots to evaluate potential non-
linearity of associations between protein-adjusted
serum-free thiols and CV events or all-cause mortality.
Non-linearity was evaluated by likelihood ratio tests,
where nested models were compared using linear or lin-
ear and cubic spline terms. In addition, a sensitivity ana-
lysis was performed in which oversampling of subjects
with higher urinary albumin concentrations was ad-
dressed by using design-based Cox proportional hazards
regression models. Two-tailed P values ≤ 0.05 were con-
sidered statistically significant.
Selection of confounding variables
In line with the guidelines for adjusting for confounders
as described previously, we used causal models (directed
acyclic graphs (DAGs) and their associated theory) to
distinguish the appropriate set of confounders for esti-
mating our effect of interest [22–24]. Based on previ-
ously established theory in our field and respecting
constraints imposed by time and logic, the DAG repre-
sents the causal mechanisms we hypothesize to be
underlying the variables at hand (scenario 1) (Add-
itional file 1: Figure S1) [9, 25–31].
Arrows depict hypothesized causal (direct) effects be-
tween variables, whereas the absence of an arrow be-
tween two variables represents the assumption of no
such direct effect. Focusing on the effect of oxidative
stress on the outcome (cardiovascular events and all-
cause mortality), we can now identify those variables for
which conditioning in the analysis is necessary in order
to obtain an unconfounded effect estimate in our
statistical analysis. This is performed by determining
unblocked causal paths in the graph from oxidative
stress to outcome, which—when left unblocked—would
bias the desired effect estimate. Consequently, we con-
cluded that conditioning on the variables gender, age,
smoking, systolic blood pressure, total cholesterol, dia-
betes, and hsCRP (as a proxy for inflammation) in the
analysis would provide an unconfounded effect estimate
of oxidative stress on the outcome.
As there could also be arguments that would lead the
arrow pointing from hsCRP (as a proxy for inflamma-
tion) to oxidative stress to point the other way around
[32], we additionally included BMI in our set of con-
founders to eliminate additional potential bias intro-
duced by that scenario (scenario 2). It has to be noted
that including BMI in the DAG (scenario 1) should
causally have no influence on the effect estimation (Add-
itional file 1: Figure S1).
Fig. 1 Distributions of tertiles of protein-adjusted serum free thiol
concentrations among survivor and non-survivors (a) and subjects
with and without a CV event (b). Tertile 1, protein-adjusted
serum free thiol concentration range < 4.65; tertile 2, protein-
adjusted serum free thiol concentration range 4.65–5.45; tertile 3,
protein-adjusted serum free thiol concentration range > 5.46
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Results
Patient characteristics
The baseline characteristics of the study population are
presented in Table 1. The mean age was 51.6 (43.3–
61.7) years, and 51% of the participants were female.
Participants in the lowest tertile of protein-adjusted
serum free thiols were significantly older and had a
higher body mass index (BMI) as compared to the
other groups (both P < 0.001). A history of cardiovascu-
lar disease was observed in 3.6% of the total cohort,
and diabetes was found in 2.4% of the total number of
participants. Mean protein-adjusted serum free thiol
level was 5.05 ± 1.02 μmol/g of protein (median
5.07 μmol/g of protein, full range 1.47–9.33 μmol/g).
Cardiovascular diseases and diabetes were more fre-
quently observed in subjects within the lowest free
thiol tertile (both P < 0.001). Higher rates of mortality
(P < 0.001) and cardiovascular events (P < 0.001) were
more often observed in subjects within the lowest ter-
tile of serum free thiols. Figure 1 shows the distribution
of serum free thiol tertiles among survivors and non-
survivors and among subjects with and without a CV
event.
Protein-adjusted serum free thiols and risk of
cardiovascular events and all-cause mortality
The mean follow-up of study participants was 7.7 ± 2.0
years, during which 402 (6.8%) cardiovascular events oc-
curred. The highest frequency of cardiovascular events was
observed in participants within the lowest tertile of protein-
adjusted serum free thiols (184 [9.3%], P < 0.001). Kaplan-
Meier survival analysis showed a significant difference in
the survival distribution between tertiles of protein-adjusted
serum free thiols among participants with and without car-
diovascular events (Fig. 2a, P < 0.0001, log-rank test). Cox
proportional hazards regression analyses and corresponding
Harrell C indices demonstrated a statistically significant
prediction of the risk of cardiovascular events (Table 2 (A),
model 1, hazard ratio [HR] per doubling of concentration
0.39 [0.29–0.51], P < 0.001). After adjustment for potential
confounding factors (age, sex, systolic blood pressure, BMI,
total cholesterol, diabetes, current smoking, and hsCRP
levels), this predictive association remained statistically sig-
nificant (Table 2 (A), model 3, HR per doubling of concen-
tration 0.68 [0.47–1.00], P = 0.048). These results remained
unchanged when the 3P-MACE was considered as the
composite endpoint. Discriminative capacity of Cox regres-
sion models significantly improved after adjustment for po-
tential confounding factors (Fig. 3a–c).
During follow-up, 316 (5.3%) subjects died. The highest
mortality rate occurred in the lowest tertile of protein-
adjusted serum-free thiols (171 [8.6%], P < 0.001). Kaplan-
Meier survival analysis showed a significantly differential
survival distribution between tertiles of protein-adjusted
serum free thiols among survivors and non-survivors
(Fig. 2b, P < 0.0001, log-rank test). Cox proportional haz-
ards regression analyses and corresponding Harrell C indi-
ces showed a significant inverse predictive association
between protein-adjusted serum free thiol concentrations
and the risk of all-cause mortality (Table 2 (B), model 1,
HR per doubling of concentration 0.30 [0.22–0.41], P <
0.001). This association remained significant after
Fig. 2 Kaplan-Meier survival distributions for tertiles of protein-adjusted serum free thiol concentrations. a Kaplan-Meier curve representing
cardiovascular disease-free survival with the highest rate of cardiovascular events occurring in the lowest tertile of protein-adjusted serum free
thiols (log-rank test, P < 0.0001). b Kaplan-Meier curve representing survival with the highest mortality rate occurring in the lowest tertile of
protein-adjusted serum free thiols (log-rank test, P < 0.0001)
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adjustment for potential confounders (Table 2 (B), model 3,
0.66 [0.44–1.00], P = 0.050). Discriminative capacity of Cox
regression models significantly improved after adjustment
for potential confounding factors (Fig. 3d–f). Restricted
cubic splines showed no significant deviances from linear
associations with either the incidence of CV events or all-
cause mortality for protein-adjusted serum free thiol con-
centrations (Additional file 2: Figure S2A-B, P = 0.258 and
P = 0.642, respectively). In weighted analyses, in which we
accounted for the oversampling of subjects with higher
urinary albumin concentrations, the results (free thiols per
doubling) differed slightly (CV events, 0.65 [95% CI 0.38–
1.10]; all-cause mortality, 0.59 [95% CI 0.34–1.02]).
Stratified analyses
Stratified analyses for the association between protein-
adjusted serum free thiols and the risk of CV events
showed consistently inverse associations in various sub-
groups, except for associations stratified by the presence
of hypertension (Pinteraction < 0.001) (Table 3; Fig. 4).
Fig. 3 a–f Receiver operating characteristic (ROC) curves with associated Harrell C indices (95% confidence interval [CI]) of the different Cox
proportional hazards regression models. a–c Discriminative ability of Cox regression models for the association between protein-adjusted
serum free thiols and cardiovascular events. d–f Discriminative ability of Cox regression models for the association between protein-adjusted
serum free thiols and all-cause mortality
Table 2 Cox proportional hazards regression models of the association between protein-adjusted serum-free thiols and potential
confounding factors with (A) cardiovascular events and (B) all-cause mortality
HR per doubling Tertiles of protein-adjusted serum-free thiols
< 4.65 μmol/g 4.65–5.46 μmol/g > 5.46 μmol/g
A. Cardiovascular events
Model 1 0.39 (0.29–0.51), P < 0.001 1.00 (reference) 0.66 (0.53–0.83), P < 0.001 0.47 (0.37–0.61), P < 0.001
Model 2 0.71 (0.51–0.97), P = 0.031 1.00 (reference) 0.94 (0.75–1.19), P = 0.600 0.82 (0.63–1.07), P = 0.135
Model 3 0.68 (0.47–1.00), P = 0.048 1.00 (reference) 1.00 (0.77–1.30), P = 0.998 0.81 (0.59–1.10), P = 0.178
B. All-cause mortality
Model 1 0.30 (0.22–0.41), P < 0.001 1.00 (reference) 0.47 (0.37–0.61), P < 0.001 0.34 (0.25–0.45), P < 0.001
Model 2 0.71 (0.50–1.01), P = 0.056 1.00 (reference) 0.77 (0.59–1.00), P = 0.048 0.73 (0.54–1.00), P = 0.049
Model 3 0.66 (0.44–1.00), P = 0.050 1.00 (reference) 0.87 (0.65–1.16), P = 0.337 0.68 (0.47–0.98), P = 0.037
Model 1: crude; model 2: model 1, age- and sex-adjusted; model 3 (based on DAG): model 2, hsCRP, current smoking, systolic blood pressure, total cholesterol,
diabetes, and BMI
P values in bold indicate statistical significance
HR hazard ratio
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Stratification by BMI and the presence of albuminuria,
hypertension, and diabetes showed significant differences
between groups. Corresponding HRs were lower for sub-
jects with a lower BMI, without hypertension, and with-
out diabetes. Conversely, HRs were lower in subjects
with albuminuria.
In subjects with a known history of CVD (n = 217,
3.6%), Cox proportional hazards regression analyses re-
vealed no significant age- and sex-adjusted associations
between protein-adjusted serum free thiol concentra-
tions and the risk of CV events (Table 4 (A), HR per
doubling of concentration 0.52 [0.23–1.19], P = 0.120).
However, we observed significant age- and sex-adjusted
associations in this subgroup between protein-adjusted
serum free thiol concentrations and the risk of all-cause
mortality when comparing the upper two tertiles with
the lowest tertile (Table 4 (B), HR per doubling of con-
centration: tertile 2, 0.48 [0.24–0.96], P = 0.038; tertile 3,
0.40 [0.16–0.99], P = 0.047). Although there was a large
difference in the sample size between subgroups of sub-
jects with and without a history of CVD (n = 217, 3.6%
vs. n = 5738, 96.4%, respectively), the discriminative cap-
acity of these models (Harrell C indices) was higher in
subjects without a known history of CVD compared to
subjects with a history of CVD (Fig. 5).
Discussion
In this large population-based cohort, we found that
protein-adjusted serum free thiol concentrations were
able to significantly predict the risk of CV events and
all-cause mortality. After adjustment for confounders,
this predictive capacity of protein-adjusted serum free
thiol concentrations (per doubling) regarding the risk of
CV events, as well as the risk of all-cause mortality,
remained statistically significant. Collectively, our results
shed light on the potential significance of serum levels of
free thiols for risk stratification in primary and second-
ary prevention settings to reduce CVD burden in the
general population.
Over the last couple of decades, increasing attention
has been paid to the role of oxidative stress in CVD,
since it may lead to endothelial dysfunction [33]. For in-
stance, it was previously shown that thiols are an oxida-
tive stress marker in subjects with an acute myocardial
infarction [34] and that plasma thiols are significantly
lower in subjects with congestive heart failure, as com-
pared to healthy subjects [35]. In the current study, we
tested the hypothesis that protein-adjusted serum free
thiols, due to the ROS-scavenging properties of free
thiols, are markers of the systemic redox status that
might be associated with the risk of CV events and mor-
tality in the general population. Indeed, our results show
that protein-adjusted serum free thiol concentrations
(per doubling) are inversely associated with the risk of
CV events after adjustment for potential confounders.
Regarding mortality, after correcting for potential con-
founders, we observed a significant association with
protein-adjusted serum free thiols. This postulation is in
line with previous findings showing that serum thiols are
independently associated with CV risk scores at the
population level [36]. As compared to this cross-
sectional study, however, the current study is much lar-
ger and of longitudinal origin (10 years of follow-up) and
Table 3 Stratified analyses for the association between protein-
adjusted serum free thiols and the risk of cardiovascular (CV)
events across various subgroups
Variable CV events (n) Total (n) HR* 95% CI Pinteraction
Overall 402 5955 0.68 0.47–1.00 0.048
Gender
Female 87 2497 0.87 0.42–1.77 0.976
Male 221 2180 0.58 0.38–0.90
BMI
< 25.0 68 1910 0.53 0.23–1.21 < 0.001
> 25.0 239 2762 0.71 0.47–1.08
Albuminuria
No 237 4285 0.71 0.46–1.08 0.008
Yes 71 394 0.52 0.24–1.12
Hypertension
No 219 4143 0.55 0.36–0.86 < 0.001
Yes 94 501 1.06 0.51–2.19
CVD history
No 271 4526 0.69 0.46–1.04 0.327
Yes 37 155 0.47 0.18–1.21
Diabetes
No 289 4592 0.67 0.45–0.98 0.012
Yes 15 73 0.79 0.16–3.83
Smoking
No 200 3402 0.78 0.49–1.27 0.484
Yes 108 1279 0.46 0.26–0.83
Alcohol consumption
No 99 1134 0.72 0.38–1.36 0.911
Yes 209 3547 0.63 0.40–0.98
Hypercholesterolemia
No 260 4372 0.61 0.41–0.90 0.062
Yes 41 242 0.83 0.28–2.42
Stratifications by BMI, albuminuria, hypertension, diabetes, and
hypercholesterolemia showed significant differences between groups.
Corresponding hazard ratios (HRs) are consistently lower for subjects with a
more favorable cardiovascular risk profile (i.e., lower BMI and the absence of
hypertension and diabetes), whereas the presence of CVD history or
albuminuria shows lower HRs as well
CV cardiovascular, HR hazard ratio, CI confidence interval, BMI body mass
index, CVD cardiovascular disease
*Adjusted for potential confounding factors (sex, age, hsCRP, current smoking,
systolic blood pressure, total cholesterol, diabetes, and BMI)
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demonstrates associations of free thiols with the occur-
rence of CV events and all-cause mortality.
In our stratified analyses, the association between pro-
tein-adjusted serum free thiols and the risk of CV events
showed no significant interaction between subjects with
and without CVD. Moreover, we demonstrated that the
association between protein-adjusted serum free thiols
and the risk of CV events was consistently inversely asso-
ciated in various subgroups, except for the association
stratified by the presence of hypertension. Free thiols were
Fig. 4 Associations between protein-adjusted serum free thiol levels and the risk of cardiovascular (CV) events across various subgroups. Hazard
ratios (HRs) are shown with corresponding 95% confidence intervals (CI). HRs represent consistently inverse associations across subgroups, with
the exception of stratification by the presence of hypertension (Pinteraction < 0.001). Stratifications by BMI, albuminuria, hypertension, diabetes, and
hypercholesterolemia show significant interactions. Corresponding HRs are consistently lower for subjects with a more favorable cardiovascular
risk profile (i.e., lower BMI and the absence of hypertension and diabetes), whereas the presence of CVD history or albuminuria shows lower HRs
as well. *HRs adjusted for potential confounding factors (sex, age, hsCRP, current smoking, systolic blood pressure, total cholesterol, diabetes, and
BMI). CV-e, cardiovascular events; BMI, body mass index; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease; HR, hazard ratio; CI,
confidence interval
Table 4 Cox proportional hazards regression models of the age- and sex-adjusted associations between protein-adjusted serum free
thiols and the risk of (A) cardiovascular events and (B) all-cause mortality in participants with and without a history of cardiovascular
disease (CVD)
HR per doubling Tertiles of protein-adjusted serum-free thiols
< 4.65 μmol/g 4.65–5.46 μmol/g > 5.46 μmol/g
A. Cardiovascular events
Total cohort 0.71 (0.51–0.97), P = 0.031 1.00 (reference) 0.94 (0.75–1.19), P = 0.600 0.82 (0.63–1.07), P = 0.135
No history of CVD 0.77 (0.54–1.08), P = 0.127 1.00 (reference) 0.96 (0.75–1.23), P = 0.761 0.83 (0.62–1.09), P = 0.181
History of CVD 0.52 (0.23–1.19), P = 0.120 1.00 (reference) 0.82 (0.42–1.61), P = 0.567 0.84 (0.38–1.86), P = 0.670
B. All-cause mortality
Total cohort 0.71 (0.50–1.01), P = 0.056 1.00 (reference) 0.77 (0.59–1.00), P = 0.048 0.73 (0.54–1.00), P = 0.049
No history of CVD 0.80 (0.54–1.18), P = 0.253 1.00 (reference) 0.81 (0.61–1.09), P = 0.159 0.81 (0.58–1.12), P = 0.206
History of CVD 0.47 (0.22–1.02), P = 0.055 1.00 (reference) 0.48 (0.24–0.96), P = 0.038 0.40 (0.16–0.99), P = 0.047
All models were age- and sex-adjusted
P values in bold indicate statistical significance
CVD cardiovascular disease, HR hazard ratio
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found to be more negatively associated with CV events in
subgroups characterized by the absence of obesity, hyper-
tension, and diabetes. Conversely, free thiols were more
negatively associated in subjects with albuminuria. Al-
though we cannot clearly explain these findings, a possible
explanation could be that albuminuria reflects ongoing
endothelial damage that leads to a stronger prediction,
whereas obesity and hypertension are merely risk factors
and their presence does not significantly contribute to the
predictive capacity. However, free thiols were more nega-
tively associated with CV events in subjects without dia-
betes. Although it could be stated that subjects with
diabetes might also show generalized manifest damage,
the majority of these diabetic subjects had a relatively
short disease duration. Therefore, we deem it unlikely that
these subjects already had diabetes-induced microvascular
complications. However, the value of free thiols in these
specific subgroups requires further study as subgroup
sizes were relatively unbalanced.
Free thiols (R-SH, sulfhydryl groups) are more accurately
reflecting the systemic in vivo redox status as compared to
many other individual oxidant or antioxidant factors and
their derivatives [5]. In the extracellular environment, thiols
are an integral part of a complex and dynamic redox signal-
ing network and possess potent antioxidant activity based
on their ability to rapidly scavenge circulating reactive
species [18]. Extracellular thiols are predominantly embed-
ded in plasma proteins, whereas a smaller percentage is
represented by low-molecular-weight (LMW) thiols, such
as cysteine, homocysteine, and glutathione (GSH) [37].
Blood proteins harbor the largest amount of redox-active
thiol groups. In this respect, albumin is quantitatively the
most important molecule within this pool (based on the ex-
istence of its single free cysteine residue, Cys34), given its
abundance and because it is capable of transporting LMW
thiols [18]. Collectively, systemic thiols circulate in both re-
duced and oxidized forms and, given their rapid and potent
antioxidant activity, have a major impact on the net extra-
cellular redox equilibrium. Therefore, measuring systemic
free thiol availability may constitute a simple, robust, and
easily reproducible method to assess the level of systemic
oxidative stress in humans. Since proteins largely determine
the total amount of measurable free thiol groups, adjusting
these to circulating total protein or albumin levels can be
regarded as an indirect approach to more precisely reflect
the total serum free thiol pool [7, 8, 10, 11, 38].
Due to the fact that free thiols are known to be recep-
tive to therapeutic modulation, our results shed light on
the potential development of therapeutic interventions.
For instance, several thiol-based antioxidants, such as N-
acetylcysteine (NAC) or glutathione (GSH), have been
investigated for their potential to restore extracellular
Fig. 5 Receiver operating characteristic (ROC) curves with associated Harrell C indices (95% confidence interval [CI]) of Cox proportional hazards
regression models in subjects with and without a history of cardiovascular disease (CVD). a, b Discriminative ability of Cox regression models for
the association between protein-adjusted serum-free thiols and cardiovascular events in both subgroups. c, d Discriminative ability of Cox
regression models for the association between protein-adjusted serum free thiols and all-cause mortality in both subgroups. CVD,
cardiovascular disease
Abdulle et al. BMC Medicine          (2020) 18:130 Page 10 of 12
thiol homeostasis in both human and animal studies
[39]. Administration of these substances may increase
the extracellular reducing capacity, though these poten-
tial effects should be carefully examined since they may
disturb the diverse physiological functions of reactive
species [40].
Strengths of the present study include the size and ex-
tensive clinical characterization of our study cohort and
the long follow-up duration. However, several limitations
also have to be taken into account. For instance, the ob-
servational nature of the study does not allow us to infer
causality between serum levels of free thiols and CV
events and all-cause mortality. In addition, given the fact
that the majority of patients were Caucasians, the
generalizability of our results in subjects with other
ethnicities remains unknown. Likewise, the current study
was carried out in the northern parts of the Netherlands;
therefore, the generalizability of our results could be de-
bated. Moreover, many arrows are absent in our directed
acyclic graph (DAG) for which arguments for their pres-
ence could be made (for example, socio-economic status
and BMI, socio-economic status and smoking, alcohol
and BMI, smoking and BMI) [41–44]. However, adding
these arrows as direct effects in Additional file 1: Figure
S1 (scenario 3) would not have altered the set of con-
founders necessary to correct for in our analysis. In that
sense, our analysis is robust to most of the underlying
causal assumptions made.
Conclusion
In conclusion, we show that protein-adjusted serum free
thiol levels are significantly predictive of the risk of CV
events and all-cause mortality in the general population.
Although free thiols might harbor great potential as an
easily measurable biomarker in the current primary and
secondary CVD prevention strategies, future prospective
studies will be required to further elucidate the clinical
relevance of serum free thiol levels in this context.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12916-020-01587-w.
Additional file 1: Figure S1. Directed Acyclic Graph (DAG) showing the
causal paths which were hypothesized to be involved in the relationship
between systemic oxidative stress and the risk of cardiovascular events
and all-cause mortality. Arrows depict hypothesized causal (direct) effects
between variables, whereas absence of an arrow between two variables
represents the assumption of no such direct effect.
Additional file 2: Figure S2 (A-B). Protein-adjusted serum free thiol
concentrations (μmol/g) show no deviances from linear associations with
either (A) the risk for CV events or (B) all-cause mortality. Estimated asso-
ciations were derived from the adjusted Cox proportional hazards regres-
sion analysis (model 3) based on restricted cubic splines with three knots.
P-values for non-linearity were P = 0.258 for CV-events and P = 0.642 for
all-cause mortality. The median of protein-adjusted serum free thiol
concentrations was taken as a reference standard (5.07 μmol/g of pro-
tein). Gray-shaded areas represent 95% confidence intervals.
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